EFErin R. Fox

Erin R. Fox

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Erin R. Fox has a total of 92 co-authors. Here are the top co-authors by number of shared publications:

  • Jesse M. Pines

    US Acute Care Solutions, Canton, OH, United States of America

    3 shared publications
  • Linda S. Tyler

    Department of Pharmacy, University of Utah Health Care, Salt Lake City, Utah

    3 shared publications
  • Mark S. Zocchi

    Center for Health Optimization and Implementation Research (CHOIR) VA Bedford Healthcare System Bedford Massachusetts USA

    3 shared publications
  • Maryann Mazer-Amirshahi

    Department of Emergency Medicine, MedStar Washington Hospital Center, Georgetown University School of Medicine , Washington, DC , USA

    3 shared publications
  • Maryann Mazer-Amirshahi

    Department of Emergency Medicine, MedStar Washington Hospital Center, Washington, USA

    3 shared publications
  • M. Christina Beckwith

    Erin Fox, Virginia M. Jones, and M. Christina Beckwith are with the Drug Information Service, University of Utah Hospitals and Clinics, Salt Lake City, Utah, USA

    2 shared publications

Latest Publications

  • Impact of Drug Shortages on Cancer Care Delivery Within the National Cancer Institute Community Oncology Research Program

    by Lauren V. Ghazal, Supriya Mohile, Kah Poh Loh, Karen Mustian, Grace Sventek, Umang Gada, Chin-Shang Li, Eva Culakova, Melyssa Foust, Judith O. Hopkins, et al.

    PURPOSE: Drug shortages represent a challenge in oncology care, with potential repercussions including suboptimal treatment options, treatment delays, and medication errors. However, there is scant evidence on how drug shortages interrupt cancer care delivery (CCD) nationally and specifically across National Cancer Institute (NCI) Community Oncology Research Program (NCORP) community oncology practices. METHODS: Between December 2020 and July 2024, 96 NCORP community oncology practices were enrolled. NCORP practice study staff completed the Drug Shortage Baseline Survey and Pharmacy Baseline Survey. The primary outcome was proportion of practices seriously affected by drug shortages (ie, encountered CCD problems [change to less effective treatments, adoption of more toxic alternatives, treatment delays, or an increase in medication errors or near misses]) in the past 3 months. Secondary outcomes included CCD problems among practices (eg, ethical dilemmas) and strategies used by practices (eg, use of alternative drugs, stockpiling). Finally, we described differences between seriously affected and nonaffected practices. RESULTS: Nearly 54% of NCORP practices were seriously affected by drug shortages in the past 3 months, with 23 drugs (including carboplatin [24.7%], leucovorin [22.6%], and cisplatin [19.4%]). Seriously affected practices were more likely to report lack of suitable alternatives (34.7% v 13.6%), substantial resources spent (70.8% v 50.0%), and change to alternative administration (73.5% v 52.3%) and were less likely to hire staff to address shortages (16.3% v 36.4%). Strategies to address shortages included using alternative drugs (91.5%), stockpiling (87.2%), and developing action plans (84.0%). Most (50.5%) practices reported experiencing an ethical dilemma related to a drug shortage. CONCLUSION: Drug shortages influenced CCD among NCORP practices. This study underscores the need for robust strategies and policies to mitigate these effects and enhance the resilience of oncology practices.


  • Stockpiling at the Onset of the COVID-19 Pandemic: An Empirical Analysis of National Prescription Drug Sales and Prices

    by Minje Park, Anita L. Carson, Erin R. Fox, Rena M. Conti

    At the onset of the coronavirus (COVID-19) pandemic, hospitals experienced a demand surge for COVID-19–related medical care while simultaneously struggling to source prescription drugs needed to manage COVID-19 patients. This is worrisome as shortfalls in the supply of essential drugs can negatively impact patient outcomes. The popular press reporting on these challenges suggests that they are caused by supply chain disruptions. However, rigorous research on the relationship between the pandemic and prescription drug supply is limited. To address this gap, we leverage a quasi-experimental design and IQVIA’s National Sales Perspectives™ data from 2018 to 2020. We focus on prescription drugs indicated for the management of COVID-19 patients and a set of control drugs (i.e., drugs not used for COVID-19). We find that in the early phases of the pandemic, hospitals stockpiled prescription drugs indicated for the management of COVID-19, making this behavior an under-recognized cause of the sourcing challenges. The sales volume of drugs indicated for COVID-19 management was concentrated in the first two months of the pandemic, after which sales decreased significantly despite a nationwide increase in COVID-19–related hospitalizations. We investigate another potential cause of stockpiling: expected price increases. Counter to concerns of price gouging, we find little evidence of price inflation for these drugs. An implication for drug manufacturers is that orders due to stockpiling by downstream buyers early on in a pandemic may need to be discounted when predicting future demand. Our results have implications for drug suppliers, hospitals, and policymakers interested in improving medical product supply chain resilience. This paper was accepted by Stefan Scholtes, healthcare management. Funding: R. M. Conti was supported by the National Science Foundation (Grant 1123649-463157) and the Sloan Foundation. Supplemental Material: The online appendices and data files are available at https://doi.org/10.1287/mnsc.2021.04150 .


  • US drug shortages compared to the World Health Organization’s Model List of Essential Medicines for Children: A cross-sectional study

    by Ram Patel, Samira Samiee-Zafarghandy, Victoria Ziesenitz, Erin R Fox, John Van Den Anker, Hilary Ong, Maryann Mazer-Amirshahi

    In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. To describe US drug shortages affecting medications on the 2019 World Health Organization (WHO) Model List of Essential Medicines for Children (EMLc). Drug shortage data from January 2014 to December 2019 were obtained from the University of Utah Drug Information Service. Shortage data for drugs on the EMLc were analyzed for the type of drug, American Hospital Formulary Service category, reason for the shortage, duration of the shortage, marketing status (generic vs brand name), and whether the agent was a single- or multisource drug. From 2014 to 2019, a total of 209 drug shortages impacted medications on the EMLc, of which 77 (36.8%) remained unresolved by 2019. Of all active shortages, 13 (6.2%) began before 2014. Resolved shortages had a median duration of 5.9 months (interquartile range [IQR], 3.6-13.2 months) while active shortages had a median duration of 18.3 months (IQR, 10.9-33.5 months; P ≤ 0.0001). The therapeutic categories most impacted by drug shortages were anti-infective agents (27.3%), central nervous system agents (12.9%), and antineoplastic agents (11.0%). The reason for the shortage was not reported in 46.4% of cases. When a reason was provided, the most common reason was manufacturing problems (29.2%) followed by supply/demand mismatch (15.8%). US drug shortages affected many medications on the WHO EMLc. Future studies should examine the global shortage climate and implications for patient care.


  • The rising cost of commonly used emergency department medications (2006–15)

    by Collin Tebo, Maryann Mazer-Amirshahi, Mark S. Zocchi, Colin Gibson, Sarah Rosenwohl-Mack, Renee Y. Hsia, Erin R. Fox, Lewis S. Nelson, Jesse M. Pines


  • Open Access

    Developing statewide remdesivir use criteria

    by Erin R Fox, Mark Shah, Russell Vinik, Sam Brown, Whitney Buckel, Brandon Webb, Janet Zarndt, Megan Evans, Pejman Mesdaghi, Hannah N Imlay, et al.

    Purpose: This report describes our process of 4 health systems coming together to agree on standard use criteria for remdesivir as a coronavirus disease 2019 (COVID-19) treatment for patients in Utah. We hope our process provides a framework for remdesivir use in other states and insights on future use of other therapeutic agents that may also be in short supply, such as vaccines and monoclonal antibodies. Summary: Emergency use authorization (EUA) criteria for COVID-19 treatments often allow for broad use of a treatment relative to limited supplies. Without national criteria, each health system must develop further rationing criteria. Health systems in Utah worked together as part of the state’s crisis standards of care workgroup to develop a framework for how to limit the EUA criteria for remdesivir to match available supplies. The 4 largest health systems were represented by infectious diseases specialists, chief medical officers, and pharmacists. The group met several times online and communicated via email over a 9-day period to develop the criteria. The clinicians agreed to use this framework to develop criteria for future therapeutics such as monoclonal antibodies. Conclusion: The unique collaboration of the 4 health systems in Utah led to statewide criteria for use of remdesivir for patients with COVID-19, ensuring similar access to this limited resource for all patients in Utah.


  • Open Access

    ASHP Foundation Pharmacy Forecast 2021: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems

    by Joseph T DiPiro, Erin R Fox, Aaron S Kesselheim, Marie Chisholm-Burns, Christopher K Finch, Christina Spivey, Jannet M Carmichael, Joy Meier, Thomas Woller, Brian Pinto, et al.

    The ASHP Foundation Pharmacy Forecast has been a valuable source of insight and guidance about our profession as it is influenced by or influences external factors in our environment. ASHP and the ASHP Research and Education Foundation (“the Foundation”) present this ninth edition of the annual Pharmacy Forecast and are pleased to disseminate the Pharmacy Forecast through AJHP, providing readers with easy access to the report. The staff of AJHP has provided substantial editorial support for this publication, and we appreciate their assistance.


  • Open Access

    COVID-19 and Drug Shortages: A Call to Action

    by Andrew G. Shuman, Erin R. Fox, Yoram Unguru

    The ever-vulnerable medication supply chain is being further strained by the COVID-19 pandemic. Pharmacists in all settings, including managed care, will need to prepare for a potential exacerbatio...


  • Open Access

    Budgeting in the time of COVID-19

    by Erin R Fox

    Projecting future drug expenses is never an easy task. This year, Tichy et al1 provide key projections that will be needed now more than ever. This year health systems will not only face unprecedented financial challenges due to the coronavirus disease 2019 (COVID-19) pandemic; they may also be facing operational challenges. The section of the ASHP Foundation’s 2020 Pharmacy Forecast report regarding “black swans” (rare events with serious consequences, as popularized by Taleb2) noted that few health-system pharmacy departments had a strategic planning process in place to successfully deal with such an event.3 Meeting the patient surge and drug shortage challenges posed by the COVID-19 pandemic in addition to planning for costly new pharmaceuticals will test even the most robust organizations.


  • An advocacy journey

    by Erin R Fox

    Imagine you just found out that your health system can’t access any vinblastine for the next 2 months. You know you have 15 patients in the middle of curative treatments. You also know that new patients will need to start curative treatment during this time. Your current stock doesn’t allow both for current patients to finish treatment and for new patients to start treatment. You know your health system will need to make some difficult decisions. Take a moment and think about the heart-wrenching patient care decisions just like this one being made every day in health systems across the country.